SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-137204
Filing Date
2023-05-05
Accepted
2023-05-05 16:52:00
Documents
13
Period of Report
2023-04-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d437694d8ka.htm   iXBRL 8-K/A 28256
2 EX-10.1 d437694dex101.htm EX-10.1 39531
  Complete submission text file 0001193125-23-137204.txt   208430

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA virx-20230427.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20230427_lab.xml EX-101.LAB 18701
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20230427_pre.xml EX-101.PRE 11687
7 EXTRACTED XBRL INSTANCE DOCUMENT d437694d8ka_htm.xml XML 3916
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-51531 | Film No.: 23894685
SIC: 2834 Pharmaceutical Preparations